60 Assessing hyaluronidase-facilitated subcutaneous immunoglobulin 20% (fSCIG 20%) pharmacokinetics, safety and tolerability in primary immunodeficiency diseases: phase 2/3 study designRichard LWasserman, Zhaoyang Li, Colin Anderson‐Smits et al.|Clinical Immunology|2024Cited by 0